BLOGS WEBSITE

Asia-Pacific Economic Corporation (APEC): ASPIRE Prize 2018 – Deadline Brought Forward

***The closing date for this opportunity has been brought forward from the 13 April to the 26 March 2018***

The APEC Science Prize for Innovation, Research and Education (ASPIRE) awards young scientists who have demonstrated both excellence in scientific research and cooperation with scientists from other APEC member economies.

The ASPIRE Prize fosters APEC’s mission to:

  • Strengthen international science and technology networks;
  • Enhance economic growth, trade and investment opportunities in harmony with sustainable development, through policies, innovative R&D and technologies, and knowledge sharing;
  • Improve linkages and efficiency between research and innovation.

The theme of the 2018 ASPIRE Prize is ‘Smart Technologies for Healthy Societies‘. This theme promotes the use of smart technologies and digital platforms to improve health care access and services to APEC member economies. The 2018 Prize can be awarded to scientists in areas such as e.g. biomedical technology, healthcare supply chains, pharmaceutical technology, point-of-care systems, wearable technology, self-help devices, artificial gene fusion, medical informatics, cell surface display techniques, robotics, nanomedicine, 3D printing and continuous manufacturing, blockchain technology and other relevant fields.

Eligibility

Nominees must be:

  • a citizen of an APEC member economy
  • under the age of 40 as of 31 December 2018

Submission Requirements & Due Date

Applications are submitted directly to the Sponsor by 26 March 2018

If you decide to apply for any of these prizes or awards, please contact Dale Godfrey.

Prior to submission please ensure that your University of Adelaide Researcher Profile page is up to date.

Further Information

This entry was posted in Awards & Prizes, Engineering, Computer & Mathematical Sciences, Funding by Award Type, Funding by Faculty, Health & Medical Sciences, Sciences. Bookmark the permalink.
 

Comments are closed.